Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UplighTED phase 3 study of subcutaneous efgartigimod PH20 in adults with thyroid eye disease
jRCT2061240092Phase 3Completed
- Sponsor
- argenx
- Start
- Feb 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) comparing Efgartigimod PH20 SC with Placebo PH20 SC (2 arms). Primary endpoint: Percentage of participants who were proptosis responders. Started Feb 2025; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on jRCT2061240092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240092.